Inclusion Criteria:

- Eligible patients will:

- have documented CIN 1 by histologic assessment as the highest grade lesion
present,

- have the lesion confined to the cervix and completely visualized,

- be 16 years or older.

Exclusion Criteria:

- any one of the following will be an excluding characteristic:

- index Pap smear showing CIN 2, CIN 3 or cancer;

- index Pap smear shows atypical glandular cells of unknown significance,
glandular dysplasia, or malignancy requiring immediate investigation;

- patients with previously identified CIN 1 by biopsy who are already in a
colposcopic surveillance program;

- unsatisfactory colposcopic exam defined as inability to see the extent of the
lesion in the endocervical canal or absence of a lesion on the ectocervix but
endocervical curettage shows CIN 1;

- pregnancy;

- prior therapy for dysplasia including medical (5FU), surgical (Laser, LEEP) or
cryotherapy;

- prior gynecologic cancer;

- prior pelvic radiation therapy;

- inability to attend outpatient follow-up visits because of geographic
inaccessibility;

- other malignancies except non-melanoma skin cancer;

- immunosuppression due to diseases such as AIDS, organ transplantation, or on
immunosuppressive medications such as prednisone, imuran or chemotherapy for
diseases like systemic lupus;

- cognitively impaired or otherwise unable to obtain written informed consent;

- extension of the CIN 1 lesion to vagina or a separate vaginal lesion showing
dysplasia;

- colposcopically visible condyloma outside of the transformation zone;

- known allergy to local analgesics;

- clinically evident vaginitis must be treated and resolved prior to entry on the
trial;

- inability to read and respond in English/French;

- failure to provide informed consent.